Details

NameSymbolSector
EIKO LIFESCIENCES LIMITEDEIKOSpecialty Chemicals
Open
52.01
High
53.9
Low
51.56
Close
51.89
Volume
8206
Exchange
bse
Time
03-Oct-2025

Outlook

Score:  

1.75

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Eiko Lifesciences is  
High Wave
Estimated Stoploss of Eiko Lifesciences is ₹  
53.9
Eiko Lifesciences has a  
Bearishℹ
 pattern. 
Formation of  
High Wave
 candle pattern indicates the trend direction of Eiko Lifesciences is  
Unpredictableℹ
. 

Trend

Eiko Lifesciences is in  
Sideways trendℹ
. 
Price of Eiko Lifesciences is  
Downℹ
 by  

3.64

%. 
Target
Buy @ 

50.6

Sell @ 

58.1

Current @ 

51.89

Volume

The trade volumes of Eiko Lifesciences have become  
Deficientℹ
The volume trend for Eiko Lifesciences is  
Bearishℹ
, but the participants are  
Weak Sellersℹ
The trade volume of Eiko Lifesciences is  

Down

 by  

29.38

% 

Valuation

The current market price of Eiko Lifesciences is  
Undervaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 66cr and total assets worth ₹ 66cr, the balance sheet of Eiko Lifesciences is:  
Balancedℹ
. 
Cashflow
Eiko Lifesciences has  
Insufficientℹ
 cash flow because there is  

Shortage

 of  

₹ 1cr

. It is  
Downℹ
 by  

0

%. 

(*Mar 2025)

10.53% i.e. ₹ 2cr earned in operatingℹ
57.89% i.e. ₹ 11cr spent in investingℹ
31.58% i.e. ₹ 6cr earned in financingℹ
0% in otherℹ
Income
The income of Eiko Lifesciences is  

₹ 10cr

 and  

Profit

 is :  

₹ 1cr

(*Jun 2025)

Eiko Lifesciences Profit is up by:  

0

% and Income is Down by:  

9.09

% 

(*Jun 2025)

The income of Eiko Lifesciences is  

₹ 11cr

 and  

Profit

 is :  

₹ 1cr

(*Mar 2025)

Eiko Lifesciences Profit is up by:  

100

% and Income is Up by:  

57.14

% 

(*Mar 2025)

The income of Eiko Lifesciences is  

₹ 7cr

 and  

Loss

 is :  

₹ 0cr

(*Dec 2024)

Eiko Lifesciences Losses increased by:  

0

% and Income is Down by:  

12.5

% 

(*Dec 2024)

By using this site you agree to the use of cookies to deliver a better site experience.